A Phase 3 interventional study of DE-117 and Latanoprost ophthalmic solution in Open Angle Glaucoma or Ocular Hypertension, sponsored by Santen Pharmaceutical Co., Ltd.. Completed at 1 site in Singapore. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. — 1 open to participants now, 2 under way, 1 of them phase 3. Glaucoma, Open-Angle · Santen Pharmaceutical Co., Ltd..
Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., this one is the 6th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2017, is one of 17 in phase 3, and was the 22nd registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. is open now, in 8 countries. Recruiting first, the newest first:
Santen SAS · Sites in Austria, Belgium, Germany and 5 more countries
Ages 18–85
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 18 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2017.
This study's enrollment of 370 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 165 across the 31 interventional studies, 196 across the 4 observational. Of the 33 that completed or were terminated, 14 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
Santen Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 1 is open to participants now.
1 of the studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: DE-117
Drug: Latanoprost ophthalmic solution
DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
Also known as: Xalatan
Mean Diurnal IOP at Month 3
The IOP (mmHg) measured in the study eye (identified at Day 1 \[baseline\]) was the efficacy measure for this study. The IOP was measured using a calibrated Goldmann applanation tonometer preferably by the same Investigator (operator) and the same authorized study staff (recorder) during the study for each subject.
Time frame: Month 3 (average of IOP at 3 time points: 09:00, 13:00, 17:00)
IOP at 9 Timepoints (First Key Secondary Efficacy Endpoint)
The IOP (mmHg) measured in the study eye (identified at Day 1 \[baseline\]) was the efficacy measure for this study. The IOP was measured using a calibrated Goldmann applanation tonometer preferably by the same Investigator (operator) and the same authorized study staff (recorder) during the study for each subject.
Time frame: 09:00, 13:00, and 17:00 at Week 1, Week 6, and Month 3.
Mean Diurnal IOP at Week 1 (Second Key Secondary Endpoint)
The IOP (mmHg) measured in the study eye (identified at Day 1 \[baseline\]) was the efficacy measure for this study. The IOP was measured using a calibrated Goldmann applanation tonometer preferably by the same Investigator (operator) and the same authorized study staff (recorder) during the study for each subject.
Time frame: Week 1
| Milestone | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|
| Started | 185 | 185 |
| Completed | 170 | 177 |
| Not completed | 15 | 8 |
The IOP (mmHg) measured in the study eye (identified at Day 1 \[baseline\]) was the efficacy measure for this study. The IOP was measured using a calibrated Goldmann applanation tonometer preferably by the same Investigator (operator) and the same authorized study staff (recorder) during the study for each subject.
| mmHg | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|
| Mean Diurnal IOP at Month 3 | 17.5 ± 0.25 | 16.8 ± 0.25 |
The IOP (mmHg) measured in the study eye (identified at Day 1 \[baseline\]) was the efficacy measure for this study. The IOP was measured using a calibrated Goldmann applanation tonometer preferably by the same Investigator (operator) and the same authorized study staff (recorder) during the study for each subject.
| mmHg | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|
| Week 1 09:00 | 19.0 ± 0.28 | 18.8 ± 0.29 |
| Week 1 13:00 | 18.4 ± 0.28 | 18.4 ± 0.29 |
| Week 1 17:00 | 18.0 ± 0.28 | 18.3 ± 0.28 |
| Week 6 09:00 | 17.8 ± 0.26 | 17.4 ± 0.26 |
| Week 6 13:00 | 17.6 ± 0.27 | 17.2 ± 0.27 |
| Week 6 17:00 | 17.5 ± 0.26 | 17.1 ± 0.27 |
| Month 3 09:00 | 17.9 ± 0.27 | 17.0 ± 0.27 |
| Month 3 13:00 | 17.2 ± 0.25 | 16.7 ± 0.26 |
| Month 3 17:00 | 17.2 ± 0.26 | 16.7 ± 0.27 |
The IOP (mmHg) measured in the study eye (identified at Day 1 \[baseline\]) was the efficacy measure for this study. The IOP was measured using a calibrated Goldmann applanation tonometer preferably by the same Investigator (operator) and the same authorized study staff (recorder) during the study for each subject.
| mmHg | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|
| Mean Diurnal IOP at Week 1 (Second Key Secondary Endpoint) | 18.5 ± 0.26 | 18.5 ± 0.27 |
Collected over An on-study AE were reported after the date of informed consent through the last study visit at Month 3. An AE was considered as treatment-emergent if the AE occurred on or after the treatment start date up to the last study visit. Treatment-emergent AEs were a subset of on-study AEs. AE reporting was executed until last study visit, 3 months later after randomization.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DE-117 Ophthalmic Solution | 0/185 (0%) | 2/185 (1.1%) | 74/185 (40%) |
| Latanoprost Ophthalmic Solution 0.005% | 0/185 (0%) | 2/185 (1.1%) | 55/185 (29.7%) |
| Event | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|
| TinnitusEar and labyrinth disorders | 1/185 | 0/185 |
| Urinary retentionRenal and urinary disorders | 1/185 | 0/185 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/185 | 1/185 |
| Food poisoningGastrointestinal disorders | 0/185 | 1/185 |
| Event | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|
| Conjunctival hyperaemiaEye disorders | 22/185 | 10/185 |
| PhotophobiaEye disorders | 10/185 | 1/185 |
| Dry eyeEye disorders | 9/185 | 4/185 |
| Corneal thickeningEye disorders | 7/185 | 2/185 |
| Eye painEye disorders | 5/185 | 6/185 |
| ConjunctivitisInfections and infestations | 3/185 | 5/185 |
| Ocular hyperaemiaEye disorders | 4/185 | 4/185 |
| Vision blurredEye disorders | 4/185 | 2/185 |
| Eye pruritusEye disorders | 2/185 | 4/185 |
| NasopharyngitisInfections and infestations | 1/185 | 4/185 |
All 370 subjects received at least 1 dose of their assigned study medication and were included in the Safety population. Data for all subjects except 1 were included in the Full Analysis Set (FAS); 1 subject in the DE-117 arm was excluded from the FAS due to no data for at least 1 post-baseline IOP measurement.
| Age, Categorical(Participants) | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 137 | 143 | 280 |
| >=65 years | 47 | 42 | 89 |
| Age, Continuous(years) | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% | Total |
|---|---|---|---|
| Mean | 54.6 ± 12.9 | 52.6 ± 13.1 | 53.6 ± 13.0 |
| Sex: Female, Male(Participants) | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% | Total |
|---|---|---|---|
| Female | 78 | 97 | 175 |
| Male | 106 | 88 | 194 |
| Ethnicity (NIH/OMB)(Participants) | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 5 |
| Not Hispanic or Latino | 166 | 173 | 339 |
| Unknown or Not Reported | 14 | 11 | 25 |
| Race (NIH/OMB)(Participants) | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 184 | 185 | 369 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | DE-117 Ophthalmic Solution | Latanoprost Ophthalmic Solution 0.005% | Total |
|---|---|---|---|
| India | 98 | 103 | 201 |
| South Korea | 21 | 20 | 41 |
| Singapore | 17 | 9 | 26 |
| Taiwan | 48 | 53 | 101 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Jan 2019, 24 months.
Results were first posted in Mar 2024, 5 years 2 months after primary completion.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 24 months is close to that.
Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omidenepag isopropyl
Santen Pharmaceutical Co., Ltd. →